SGYP - Synergy Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.3103
+0.0273 (+9.65%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.2830
Open0.2876
Bid0.3123 x 800
Ask0.3199 x 1800
Day's Range0.2761 - 0.3200
52 Week Range0.0700 - 2.2600
Volume3,870,375
Avg. Volume13,464,322
Market Cap76.966M
Beta (3Y Monthly)7.25
PE Ratio (TTM)N/A
EPS (TTM)-0.5620
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Synergy Pharmaceuticals Inc. - SGYP

    NEW YORK, Feb. 13, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Synergy Pharmaceuticals Inc. ("Synergy" or the "Company") (NASDAQ:  SGYP).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. Following this news, Synergy's stock price fell $0.97 per share, or 69.3%, to close at $0.43 per share on October 26, 2018.

  • The Wall Street Journal3 days ago

    [$$] Firm Retention Summary: Synergy Pharmaceuticals Inc.

    This is a summary of a request from Synergy Pharmaceuticals Inc. to hire Togut Segal & Segal LLP as co-counsel, filed Jan. 31 with the U.S. Bankruptcy Court in New York.

  • GlobeNewswire4 days ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Synergy Pharmaceuticals Inc. (SGYP)

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Synergy Pharmaceuticals Inc. (“Synergy” or the “Company”) (SGYP). The investigation concerns whether Synergy and certain of its officers and/or directors have violated federal securities laws.

  • GlobeNewswire5 days ago

    SYNERGY PHARMACEUTICALS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that it filed a securities class action lawsuit in the United States District Court for the Eastern District of New York against Synergy Pharmaceuticals, Inc.

    Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of those who acquired Synergy Pharmaceuticals Inc., (“Synergy” or the “Company”) (SGYP) securities between September 7, 2017 through October 25, 2018, inclusive (the “Class Period”) against certain of the Company’s executives and officers. This action is captained McMullen v. Hamilton, et al., No. 1:19-cv-00825.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.

    Synergy Pharmaceuticals Inc NASDAQ/NGS:SGYPView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for SGYP with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding SGYP totaled $2.44 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • ACCESSWIRE22 days ago

    Small Cap Stocks Breaking Out

    HENDERSON, NV / ACCESSWIRE / January 25, 2019 / Below are some of the best small-micro cap opportunities on the market today. One that may want to look at right away is Gopher Protocol Inc. (GOPH) , an ...

  • The Wall Street Journallast month

    [$$] Transparency Takes Center Stage in Pharma Bankruptcy

    A Justice Department lawyer called for all bankruptcy professionals to improve transparency regarding potential conflicts of interest, likening recent disclosures filed by Centerview Partners to a “cat ...

  • The Wall Street Journallast month

    [$$] Charlotte Russe Reassesses Its Future, Including Sale or Bankruptcy

    Charlotte Russe Inc., a mall-based fast-fashion retailer, is reassessing its future, including a possible sale or bankruptcy, less than a year after reaching a deal with its lenders to slash debt.

  • The Wall Street Journallast month

    [$$] Synergy Pharmaceuticals Wins Court Approval for Extended Sale Process

    Cos., formerly Valeant Pharmaceuticals International Inc., after agreeing to delay the process by two weeks. During a hearing Friday at the U.S. Bankruptcy Court in New York, Judge James Garrity Jr. said he was satisfied with the extension and was pleased to keep the process rolling forward. The judge had previously expressed concern about moving the sale along too quickly.

  • ACCESSWIRElast month

    These 4 Healthcare Stocks Are Making Moves

    CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals Inc (SGYP), Novavax Inc (NVAX), and Epizyme Inc (EPZM) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) opened Friday with the Company's shares trading at $0.63 per share, well above the $0.53 close back in October, as well as steadily ahead of $0.59 per share price point from early last month.

  • ACCESSWIRElast month

    These 4 Healthcare Stocks Are Kicking Off The New Year With A Bang

    CORAL GABLES, FL / ACCESSWIRE / January 2, 2019 / With the new year only a few days old, the healthcare sector is already showing signs that this year may prove exciting for the market. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (PHGRF) (PHGI), Regional Health Properties, Inc (NYSE: RHE), Genocea Biosciences Inc (NASDAQ: GNCA), and Synergy Pharmaceutical, Inc (NASDAQ: SGYP) are 4 healthcare stocks heating up on Wednesday.

  • ACCESSWIRE2 months ago

    4 Pharma Stocks Gaining Speed on Monday (12/31/18)

    From data-based care solutions to improved treatment options, Premier Health Group (PHGRF) (PHGI), Rite Aid Corporation (RAD), Adamis Pharmaceuticals Corp (ADMP), and Synergy Pharmaceuticals Inc (SGYP) are 4 pharma stocks heating up on Monday. Synergy Pharmaceuticals, Inc (SGYP) a biopharmaceutical company that is largely focused on developing originative gastrointestinal therapies, announced earlier this month that it had entered into an agreement with Bausch Health Companies Inc. through which Bausch Health would acquire substantially all of Synergy's assets, including all rights to TRULANCE®,dolcanatide and related intellectual property, for approximately $200 million in cash.

  • ACCESSWIRE2 months ago

    These 4 Pharma Stocks Could Test December Highs

    CORAL GABLES, FL / ACCESSWIRE / December 21, 2018 / The pharmaceutical industry is predicated on the notion that treatments for various ailments can always be improved upon, and patients suffering from these diseases both demand and need better treatment options. As pharmaceutical companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety may benefit from these efforts. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals, Inc (SGYP), Pieris Pharmaceuticals, Inc (PIRS), and Obalon Therapeutics Inc (OBLN) are 4 pharma stocks representing companies invested in creating the best quality drug treatments for their patients.

  • ACCESSWIRE2 months ago

    These 4 Pharma Stocks Are Heating Up

    CORAL GABLES, FL / ACCESSWIRE / December 19, 2018 / The pharmaceutical industry is booming with innovative approaches to developing quality treatment options for patients around the world. As demand for ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Achillion Pharmaceuticals and Synergy Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 18, 2018 / Shares of Achillion Pharmaceuticals were in the red on Monday as traders waited for interim clinical-trial data from the company. Synergy Pharmaceuticals saw its shares explode on news from Cipher Pharmaceuticals Inc. announcing that its New Drug Submission for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide from Synergy earlier this year.

  • ACCESSWIRE2 months ago

    4 Stocks to Watch Pre-Market on Tuesday 12/18/2018

    / On Tuesday 12/18/2018, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals Inc. (SGYP), New Age Beverages Corporation (NBEV) and Uxin Limited (UXIN) are seeing pre-market "buzz". Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) has seen a strong month of bullish trading and shares of the company have climbed by as much as 31% over the last 30 days. The Company has been focusing on a growth strategy with key announcements which continue to build new interest.

  • ACCESSWIRE2 months ago

    4 Stocks Providing Investor Opportunity Right Now

    On Monday 12/17/2018, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), Diffusion Pharmaceuticals Inc. (DFFN), Evofem Biosciences, Inc. (EVFM) and Synergy Pharmaceuticals Inc. (SGYP) are presenting investors with upside opportunity ahead of Christmas and the 2019 New Year. Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) a company you may have not heard of yet, has seen a strong month of bullish trading and shares of the company have climbed by as much as 31% over the last 30 days. The Company has been focusing on a growth strategy with key announcements which continue to build new interest.

  • The Wall Street Journal2 months ago

    [$$] Neiman Marcus Asks Court to Dismiss Lawsuit by Marble Ridge

    Neiman Marcus filed a counter lawsuit Friday against bondholder Marble Ridge Capital, accusing the investment firm of spreading false statements about the company being in default under its debt documents....

  • CNW Group2 months ago

    Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada

    MISSISSAUGA, ON , Dec. 17, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) today  announced that its New Drug Submission ("NDS") for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide (branded as TRULANCE® in the U.S.) from Synergy Pharmaceuticals Inc. (SGYP) ("Synergy") in February 2018 . It is estimated that one in four Canadians has symptoms of constipation and an estimated 38% of Canadians report constipation within the previous 12 months1.

  • The Wall Street Journal2 months ago

    [$$] Synergy Pharmaceuticals Moves Forward on Path Toward Sale

    During a hearing Thursday at the U.S. Bankruptcy Court in New York, Judge James Garrity Jr. expressed concern about moving too quickly but authorized the company to continue to pay employees, access bank accounts and maintain other routine operations. Inc., formerly known as Valeant Pharmaceuticals International Inc., for around $200 million in cash.